Aarti Drugs reported a robust start to FY27, with consolidated revenue rising 19% year-on-year to ₹703.6 crore in Q1FY27. Operating profitability strengthened significantly as EBITDA grew 30% to ₹96.9 crore and margins expanded by 120 basis points to 13.8%. Despite the operational strength, consolidated profit after tax (PAT) declined 7% to ₹50.1 crore, primarily due to a one-time principal tax refund of approximately ₹15 crore recorded in Q1FY26 and a capital work-in-progress (CWIP) write-off of roughly ₹2 crore in the current quarter. Excluding these non-recurring items, PAT growth would have stood at 29% year-on-year.

Financial Performance

The company’s top-line growth was broad-based, driven by volume increases and improved realizations across its Active Pharmaceutical Ingredients (API) and Specialty Chemicals portfolios. Gross profit surged 27% year-on-year to ₹276.0 crore, reflecting a gross margin expansion of 250 basis points to 39.3%. Profit before tax (PBT) grew 35% to ₹69.2 crore, with PBT margin expanding by 120 basis points to 9.9%.

Segmental Highlights

Revenue from APIs, the largest contributor, grew 11% year-on-year to ₹510.4 crore. The Specialty Chemicals segment saw a dramatic surge of 150% year-on-year, reaching ₹82.6 crore from ₹33.1 crore, driven by higher demand and favorable pricing. Formulation revenue increased modestly by 7% to ₹86.2 crore, while Intermediates & Others grew 26% to ₹24.3 crore.

On a standalone basis, revenue grew 20% year-on-year to ₹627.6 crore, contributing 89% to consolidated totals. Domestic revenue outpaced exports, growing 25% year-on-year compared to 12% for exports, accounting for 68% and 32% of standalone revenue respectively.

Operational Updates and Outlook

Adhish Patil, CFO & COO of Aarti Drugs Limited, attributed the performance to disciplined execution and a recovery in pricing environments. He noted that the Sayakha facility continued its planned ramp-up, operating at nearly 65% utilization, which is progressively enhancing backward integration capabilities. Additionally, the company is expanding its oral solid dosage (OSD) production capacity through brownfield developments in Baddi, Himachal Pradesh, expected to double output.

Patil emphasized that USFDA and UK approvals remain key growth drivers for expansion into regulated markets. The company aims to leverage operational efficiencies and capacity utilization improvements to strengthen medium-term margin performance despite global volatility.

Aarti Drugs has finalized a significant leadership transition to strengthen its governance framework, with changes effective October 1, 2026. The Board of Directors approved the elevation of Rashesh C. Gogri to Chairman in addition to his existing role as Managing Director, and the appointment of Adhish P. Patil as Managing Director. Concurrently, Prakash M. Patil will retire from his executive roles as Chairman, Managing Director, and Chief Executive Officer after nearly a decade of leadership since 2014.

Leadership Transition Details

The restructuring aims to balance continuity with renewal by promoting internal leaders who possess deep institutional knowledge. The following table outlines the key appointments and departures:

Rashesh C. Gogri, who has served as Managing Director since September 2014 and previously as Whole-time Director from October 2012, brings over 27 years of experience in production, marketing, and project implementation. He also serves as Vice-Chairman & Managing Director of Aarti Industries Limited and Chairman of Aarti Pharmalabs Limited.

Adhish P. Patil, currently the Chief Financial Officer since April 2014, will assume the role of Managing Director. He holds an MBA in Finance and Marketing from the University of Florida's Warrington College of Business Administration, where he graduated as a gold medallist. His appointment is subject to shareholder approval at the ensuing Annual General Meeting.

Strategic Implications

Prakash M. Patil, who has been associated with Aarti Drugs since its inception in 1984, will step back from executive responsibilities but will continue to provide guidance and strategic support to ensure a smooth transition. This move reflects a structured approach to succession planning, preserving technical expertise while positioning the company for faster execution across manufacturing, R&D, and commercial functions.

What the Numbers Show

The retention of senior leadership within the organization signals stability for investors. By elevating executives who have grown within the company, Aarti Drugs mitigates the risks often associated with external hires. The transition maintains the company's long-term strategic direction, focusing on scaling operations in Active Pharmaceutical Ingredients (APIs) and specialty chemicals through its 14 manufacturing facilities across Maharashtra, Gujarat, and Himachal Pradesh.